These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Clinical Utility of Highly Purified 10% Liquid Intravenous Immunoglobulin in Kawasaki Disease.
    Author: Oda T, Nagata H, Nakashima Y, Nanishi E, Takada Y, Nishimura M, Kubo E, Hatae K, Ohga S.
    Journal: J Pediatr; 2019 Nov; 214():227-230. PubMed ID: 31351682.
    Abstract:
    Compared with a 5% intravenous immunoglobulin, a 10% intravenous immunoglobulin as the first-line treatment of Kawasaki disease significantly reduced the fever duration (10 vs 13 hours, P = .022) among the responders, and the interval to adjunctive therapy for nonresponders (47 vs 49 hours, P = .035). There were no severe adverse events.
    [Abstract] [Full Text] [Related] [New Search]